Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial

Journal:
Nature Medicine
Published:
Affiliations:
20
Authors:
24
Institutions Authors Share
Actuate Therapeutics, United States of America (USA)
3.000000
0.13
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States of America (USA)
2.000000
0.08
Mayo Clinic, United States of America (USA)
2.000000
0.08
University of Arizona Cancer Center (UACC), United States of America (USA)
1.000000
0.04
Brown University Health, United States of America (USA)
1.000000
0.04
Metro-Minnesota Community Oncology Research Consortium (MMCORC), United States of America (USA)
1.000000
0.04
Fred Hutchinson Cancer Center, United States of America (USA)
1.000000
0.04
Biomedical Research Institute (INCLIVA), Spain
1.000000
0.04
University of Michigan (U-M), United States of America (USA)
1.000000
0.04
Centre Hospitalier Universitaire de Lille (CHU Lille), France
1.000000
0.04
Institute of Cancer Research (ICO), France
1.000000
0.04
University of Wisconsin Carbone Cancer Center (UWCCC), United States of America (USA)
1.000000
0.04
Florida Cancer Specialists and Research Institute (FCS), United States of America (USA)
1.000000
0.04
Oregon Health and Science University (OHSU), United States of America (USA)
1.000000
0.04
Bergonié Cancer Institute, France
1.000000
0.04
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada
1.000000
0.04
Developmental Therapeutics, United States of America (USA)
1.000000
0.04
Harvest Integrated Research Organization (HiRO), United States of America (USA)
1.000000
0.04
Summit Analytical, United States of America (USA)
1.000000
0.04
Mayo Clinic Hospital - Phoenix, United States of America (USA)
1.000000
0.04